Transplants for Glioblastoma

Jian Wang*, A. J.A. Terzis, Karen S. Aboody, Per Oyvind Enger, Rolf Bjerkvig

*Corresponding author for this work

    Research output: Chapter in Book/Report/Conference proceedingChapterpeer-review


    Of the primary brain tumors, intracranial neoplasms that originate from neuroglial cells are the most frequent and are collectively known as gliomas. The most malignant form is the glioblastoma multiforme (GBM), which is composed of poorly differentiated neoplastic cells with areas of vascular proliferation and/or necrosis. Surgery and radiotherapy and/or chemotherapy are the main treatment modalities currently available to patients with primary brain tumors. The continued dismal prognosis of glioblastomas has led to an increased focus on new treatment principles for the disease, including, but not limited to, gene therapy (thymidine-kinase suicide therapy, antisense inhibition of tumor growth factor receptors, and conditionally lethal viral vectors), immunotherapy (antibody, tumor cell vaccines, and adoptive transfer of activated lymphocytes), and antiangiogenesis approaches. This chapter focuses on the current use and limitations of various animal models to study glioma growth and progression, and the potential use of cell-based therapies toward the disease. It also highlights some important areas of research related to cell therapies of GBMs.

    Original languageEnglish
    Title of host publicationCellular Transplantation
    Subtitle of host publicationFrom Laboratory to Clinic
    Number of pages8
    ISBN (Electronic)9780123694157
    ISBN (Print)9780080469041
    Publication statusPublished - 2007


    Dive into the research topics of 'Transplants for Glioblastoma'. Together they form a unique fingerprint.

    Cite this